{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+prefilled+injector+pen",
    "query": {
      "intervention": "Placebo prefilled injector pen"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T01:22:12.709Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04306471",
      "title": "Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.",
          "type": "DRUG"
        },
        {
          "name": "Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Leonardo Clavijo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 32,
      "start_date": "2020-02-24",
      "completion_date": "2022-02-04",
      "has_results": false,
      "last_update_posted_date": "2020-03-13",
      "last_synced_at": "2026-09-27T01:22:12.709Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04306471"
    },
    {
      "nct_id": "NCT03985384",
      "title": "Semaglutide Treatment On Coronary Progression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Semaglutide 2 MG/1.5 ML Subcutaneous Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2019-04-30",
      "completion_date": "2022-12-27",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-09-27T01:22:12.709Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03985384"
    },
    {
      "nct_id": "NCT04249232",
      "title": "Abaloparatide and Pelvic Fracture Healing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fracture of Pelvis (Disorder)"
      ],
      "interventions": [
        {
          "name": "Abaloparatide 80 micrograms per Pen dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo prefilled injector pen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-09-17",
      "completion_date": "2024-04-25",
      "has_results": false,
      "last_update_posted_date": "2024-06-14",
      "last_synced_at": "2026-09-27T01:22:12.709Z",
      "location_count": 3,
      "location_summary": "New York, New York • Valhalla, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04249232"
    },
    {
      "nct_id": "NCT02660736",
      "title": "Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Albiglutide Liquid Auto-injector",
          "type": "DRUG"
        },
        {
          "name": "Albiglutide Lyophilized DCC Pen Injector",
          "type": "DRUG"
        },
        {
          "name": "Placebo Liquid Auto-injector",
          "type": "DRUG"
        },
        {
          "name": "Placebo Lyophilized DCC Pen injector",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 59,
      "start_date": "2016-02",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-11-09",
      "last_synced_at": "2026-09-27T01:22:12.709Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02660736"
    },
    {
      "nct_id": "NCT04306081",
      "title": "Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peripheral Arterial Disease"
      ],
      "interventions": [
        {
          "name": "Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.",
          "type": "DRUG"
        },
        {
          "name": "Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Leonardo Clavijo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 86,
      "start_date": "2017-12-14",
      "completion_date": "2021-03-30",
      "has_results": false,
      "last_update_posted_date": "2020-03-12",
      "last_synced_at": "2026-09-27T01:22:12.709Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04306081"
    },
    {
      "nct_id": "NCT04741074",
      "title": "Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "CKD",
        "Diabetic Kidney Disease",
        "Type 2 Diabetes Mellitus in Obese",
        "Obesity",
        "Severe Obesity"
      ],
      "interventions": [
        {
          "name": "Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Geisinger Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-07-23",
      "completion_date": "2023-01-31",
      "has_results": true,
      "last_update_posted_date": "2024-02-09",
      "last_synced_at": "2026-09-27T01:22:12.709Z",
      "location_count": 2,
      "location_summary": "Danville, Pennsylvania • Wilkes-Barre, Pennsylvania",
      "locations": [
        {
          "city": "Danville",
          "state": "Pennsylvania"
        },
        {
          "city": "Wilkes-Barre",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04741074"
    },
    {
      "nct_id": "NCT02683746",
      "title": "Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Lyophilized albiglutide DCC pen injector",
          "type": "DRUG"
        },
        {
          "name": "Lyophilized albiglutide DCC pen injector matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Albiglutide liquid auto-injector",
          "type": "DRUG"
        },
        {
          "name": "Albiglutide liquid auto-injector matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 308,
      "start_date": "2016-03-16",
      "completion_date": "2017-05-15",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-09-27T01:22:12.709Z",
      "location_count": 70,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02683746"
    },
    {
      "nct_id": "NCT03015519",
      "title": "A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Albiglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-08-14",
      "completion_date": "2020-04-20",
      "has_results": false,
      "last_update_posted_date": "2019-01-17",
      "last_synced_at": "2026-09-27T01:22:12.709Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Morehead City, North Carolina • El Paso, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03015519"
    }
  ]
}